About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Therapeutic Advances in Medical Oncology
›
top-articles
Therapeutic Advances in Medical Oncology
4.1
(top 10%)
impact factor
1.1K
(top 20%)
papers
24.1K
(top 10%)
citations
67
(top 10%)
h
-index
4.2
(top 10%)
impact factor
1.3K
all documents
26.8K
doc citations
110
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
An overview of the c-MET signaling pathway
Therapeutic Advances in Medical Oncology
2011
647
2
Pharmacologic resistance in colorectal cancer: a review
Therapeutic Advances in Medical Oncology
2016
385
3
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Therapeutic Advances in Medical Oncology
2014
378
4
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Therapeutic Advances in Medical Oncology
2010
323
5
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
Therapeutic Advances in Medical Oncology
2018
317
6
c-MET as a potential therapeutic target and biomarker in cancer
Therapeutic Advances in Medical Oncology
2011
295
7
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Therapeutic Advances in Medical Oncology
2015
267
8
Review: Targeting the Hedgehog pathway in cancer
Therapeutic Advances in Medical Oncology
2010
262
9
5-fluorouracil and cardiotoxicity: a review
Therapeutic Advances in Medical Oncology
2018
255
10
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Therapeutic Advances in Medical Oncology
2016
240
11
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Therapeutic Advances in Medical Oncology
2019
240
12
Circulating tumour cells: their utility in cancer management and predicting outcomes
Therapeutic Advances in Medical Oncology
2010
224
13
Treatment of uveal melanoma: where are we now?
Therapeutic Advances in Medical Oncology
2018
224
14
CDK4/6 inhibition in breast cancer: current practice and future directions
Therapeutic Advances in Medical Oncology
2018
218
15
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Therapeutic Advances in Medical Oncology
2018
200
16
Nivolumab in NSCLC: latest evidence and clinical potential
Therapeutic Advances in Medical Oncology
2015
196
17
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Therapeutic Advances in Medical Oncology
2014
189
18
Radiation effects on antitumor immune responses: current perspectives and challenges
Therapeutic Advances in Medical Oncology
2018
185
19
Predictive and prognostic molecular markers for cancer medicine
Therapeutic Advances in Medical Oncology
2010
178
20
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
Therapeutic Advances in Medical Oncology
2014
178
21
Health-related quality of life and cancer clinical trials
Therapeutic Advances in Medical Oncology
2011
173
22
Cancer-induced muscle wasting: latest findings in prevention and treatment
Therapeutic Advances in Medical Oncology
2017
154
23
Use of cold-atmospheric plasma in oncology: a concise systematic review
Therapeutic Advances in Medical Oncology
2018
151
24
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
Therapeutic Advances in Medical Oncology
2013
149
25
An update on treatment options for pancreatic adenocarcinoma
Therapeutic Advances in Medical Oncology
2019
144
26
Nivolumab in melanoma: latest evidence and clinical potential
Therapeutic Advances in Medical Oncology
2015
124
27
Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies
Therapeutic Advances in Medical Oncology
2015
123
28
PD-L1 expression testing in non-small cell lung cancer
Therapeutic Advances in Medical Oncology
2018
120
29
Overcoming docetaxel resistance in prostate cancer: a perspective review
Therapeutic Advances in Medical Oncology
2012
114
30
Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications
Therapeutic Advances in Medical Oncology
2017
110
31
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
Therapeutic Advances in Medical Oncology
2019
107
32
Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables
Therapeutic Advances in Medical Oncology
2011
106
33
ALK
inhibitors in non-small cell lung cancer: the latest evidence and developments
Therapeutic Advances in Medical Oncology
2016
106
34
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
Therapeutic Advances in Medical Oncology
2015
105
35
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Therapeutic Advances in Medical Oncology
2018
105
36
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Therapeutic Advances in Medical Oncology
2015
104
37
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
Therapeutic Advances in Medical Oncology
2018
104
38
The role of the c-Met pathway in lung cancer and the potential for targeted therapy
Therapeutic Advances in Medical Oncology
2011
103
39
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Therapeutic Advances in Medical Oncology
2018
102
40
Clinical assessment of immune-related adverse events
Therapeutic Advances in Medical Oncology
2018
101
41
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Therapeutic Advances in Medical Oncology
2018
101
42
Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies
Therapeutic Advances in Medical Oncology
2018
97
43
Genotype-driven therapies for non-small cell lung cancer: focus on
EGFR
,
KRAS
and
ALK
gene abnormalities
Therapeutic Advances in Medical Oncology
2011
96
44
BRCA
mutation in ovarian cancer: testing, implications and treatment considerations
Therapeutic Advances in Medical Oncology
2017
96
45
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Therapeutic Advances in Medical Oncology
2020
94
46
Tumor heterogeneity in the clinic: is it a real problem?
Therapeutic Advances in Medical Oncology
2014
93
47
Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications
Therapeutic Advances in Medical Oncology
2016
93
48
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy
versus
lenvatinib alone for advanced hepatocellular carcinoma
Therapeutic Advances in Medical Oncology
2021
91
49
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Therapeutic Advances in Medical Oncology
2011
90
50
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Therapeutic Advances in Medical Oncology
2012
87
site/software ©
exaly
; All materials licenced under
CC by-SA
.